ArticleAnnals of hematology2025

A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.

Guillermo Garcia-Manero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.